Janux Therapeutics, Inc. Common Stock

In the latest quarter, 6 analysts provided ratings for Janux Therapeutics (NASDAQ:JANX), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 1 0 0 0 2M Ago 2 1 0 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $63.83, along with a high estimate of $100.00 and a low estimate of $48.00. Marking an increase of 130.68%, the current average surpasses the previous average price target of $27.67. Analyzing Analyst Ratings: A Detailed Breakdown A comprehensive examination of how financial experts perceive Janux Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Soumit Roy JonesTrading Announces Buy $70.00 - Kaveri Pohlman BTIG Announces Buy $62.00 - Josh Schimmer Cantor Fitzgerald Announces Overweight $100.00 - Geoff Meacham B of A Securities Raises Buy $48.00 $24.00 Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $50.00 $35.00 David Driscoll Wedbush Raises Outperform $53.00 $24.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether ...Full story available on Benzinga.com

Related tickers: JANX.

Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.

Related tickers: LGND, ANIP, ADMA, JANX.